Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Scribe Therapeutics, Inc. (SCTX) is the issuer covered by a Schedule 13G reporting beneficial ownership of its common stock as of September 30, 2026. AH Bio Fund II, L.P. reported 2,385,075 shares (12.6%), and AH Bio Fund III, L.P. reported 697,650 shares (3.7%); their respective general partners, AH Equity Partners Bio II, L.L.C. and AH Equity Partners Bio III, L.L.C., reported the same holdings.
Marc L. Andreessen and Benjamin A. Horowitz, managing members of both general partners, each reported shared voting and dispositive power over 3,082,725 shares (16.3%); neither reported sole voting or dispositive power. The shares are held directly by the funds, including as nominees for other named entities.
Key Figures
AH Bio Fund II beneficially owned shares:2,385,075 sharesAH Bio Fund II ownership:12.6%AH Bio Fund III beneficially owned shares:697,650 shares+3 more
6 metrics
AH Bio Fund II beneficially owned shares2,385,075 sharesAs of September 30, 2026
AH Bio Fund II ownership12.6%As of September 30, 2026
AH Bio Fund III beneficially owned shares697,650 sharesAs of September 30, 2026
AH Bio Fund III ownership3.7%As of September 30, 2026
Shared voting and dispositive power reported by Marc L. Andreessen and Benjamin A. Horowitz3,082,725 shares eachEach reported 16.3% as of September 30, 2026
Shares outstanding18,931,680 sharesAs of August 31, 2026; basis for the reported ownership percentages
Key Terms
beneficial ownership, sole voting power, shared voting power, shared dispositive power, +1 more
5 terms
beneficial ownershipregulatory
"beneficial ownership of the Issuer's securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
sole voting powerregulatory
"Sole Voting Power"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
shared voting powerregulatory
"Shared Voting Power"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerregulatory
"Shared Dispositive Power"
as nomineetechnical
"as nominee for AH Bio Fund II-B, L.P."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many SCTX shares did AH Bio Fund II report?
AH Bio Fund II reported beneficial ownership of 2,385,075 SCTX common shares as of September 30, 2026; its general partner, AH Equity Partners Bio II, L.L.C., reported the same amount.
How many SCTX shares did Marc L. Andreessen and Benjamin A. Horowitz report?
Marc L. Andreessen and Benjamin A. Horowitz each reported shared voting and dispositive power over 3,082,725 shares, equal to 16.3% of the class as of September 30, 2026. Neither reported sole voting or dispositive power.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Scribe Therapeutics Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
811033109
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
811033109
1
Names of Reporting Persons
AH Bio Fund II, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,385,075.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,385,075.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,385,075.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
12.6 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
811033109
1
Names of Reporting Persons
AH Equity Partners Bio II, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,385,075.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,385,075.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,385,075.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
12.6 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
811033109
1
Names of Reporting Persons
AH Bio Fund III, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
697,650.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
697,650.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
697,650.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.7 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
811033109
1
Names of Reporting Persons
AH Equity Partners Bio III, L.L.C.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
697,650.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
697,650.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
697,650.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.7 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
811033109
1
Names of Reporting Persons
Marc L. Andreessen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,082,725.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,082,725.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,082,725.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
16.3 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP Number(s):
811033109
1
Names of Reporting Persons
Benjamin A. Horowitz
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,082,725.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,082,725.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,082,725.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
16.3 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Scribe Therapeutics Inc.
(b)
Address of issuer's principal executive offices:
1150 Marina Village Parkway, Alameda, CA, 94501.
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
AH Bio Fund II, L.P. ("AH Bio II")
AH Equity Partners Bio II, L.L.C. ("AH EP Bio II")
AH Bio Fund III, L.P. ("AH Bio III")
AH Equity Partners Bio III, L.L.C. ("AH EP Bio III")
Marc L. Andreessen ("Andreessen")
Benjamin A. Horowitz ("Horowitz")
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)
Address or principal business office or, if none, residence:
The address for each of the Reporting Persons is:
Andreessen Horowitz
2865 Sand Hill Road, Suite 101
Menlo Park, CA 94025
(c)
Citizenship:
AH Bio II, AH EP Bio II, AH Bio III and AH EP Bio III were all organized in Delaware. Andreessen and Horowitz are both United States citizens.
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP Number(s):
811033109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
The Reporting Persons' beneficial ownership of the Issuer's securities consists of (i) 2,385,075 shares of common stock directly held by AH Bio II for itself and as nominee for AH Bio Fund II-B, L.P. ("AH Bio II-B") and (ii) 697,650 shares of common stock directly held by AH Bio III for itself and as nominee for AH Bio Fund III-B, L.P. ("AH Bio III-B"), AH Bio Fund III-Q, L.P. ("AH Bio III-Q") and CLF Partners II, LP ("CLF II").
AH EP Bio II is the general partner of AH Bio II and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer held of record by AH Bio II for itself and as nominee for AH Bio II-B. Andreessen and Horowitz are managing members of AH EP Bio II and may be deemed to have shared voting and shared dispositive power over the shares held of record by AH Bio II for itself and as nominee.
AH EP Bio III is the general partner of AH Bio III and may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer held of record by AH Bio III for itself and as nominee for AH Bio III-B, AH Bio III-Q and CLF II. Andreessen and Horowitz are managing members of AH EP Bio III and may be deemed to have shared voting and shared dispositive power over the shares held of record by AH Bio III for itself and as nominee.
(b)
Percent of class:
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 18,931,680 shares of common stock outstanding as of August 31, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on September 2, 2026.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of September 30, 2026 and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Under certain circumstances set forth in the limited partnership agreements of each of AH Bio II, AH Bio II-B, AH Bio III, AH Bio III-B, AH Bio III-Q, and CLF II and the limited liability company agreements of AH EP Bio II and AH EP Bio III, the general partner and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by each such entity of which they are a partner or a member, as the case may be.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
AH Bio Fund II, L.P.
Signature:
/s/ Phil Hathaway
Name/Title:
By AH Equity Partners Bio II, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 1)
Date:
11/16/2026
AH Equity Partners Bio II, L.L.C.
Signature:
/s/ Phil Hathaway
Name/Title:
By Phil Hathaway, Chief Operating Officer
Date:
11/16/2026
AH Bio Fund III, L.P.
Signature:
/s/ Phil Hathaway
Name/Title:
By AH Equity Partners Bio III, L.L.C., Its General Partner, By Phil Hathaway, Chief Operating Officer (See Note 2)
Date:
11/16/2026
AH Equity Partners Bio III, L.L.C.
Signature:
/s/ Phil Hathaway
Name/Title:
By Phil Hathaway, Chief Operating Officer
Date:
11/16/2026
Marc L. Andreessen
Signature:
/s/ Phil Hathaway
Name/Title:
By Phil Hathaway, Attorney-in-Fact
Date:
11/16/2026
Benjamin A. Horowitz
Signature:
/s/ Phil Hathaway
Name/Title:
By Phil Hathaway, Attorney-in-Fact
Date:
11/16/2026
Comments accompanying signature: Note 1: AH Bio Fund II, L.P. for itself and as nominee for AH Bio Fund II-B, L.P.
Note 2: AH Bio Fund III, L.P. for itself and as nominee for AH Bio Fund III-B, L.P., AH Bio Fund III-Q, L.P. and CLF Partners II, LP.
Exhibit Information
Exhibit 24.1 Power of Attorney for Marc L. Andreessen, dated June 23, 2023.
Exhibit 24.2 Power of Attorney for Benjamin A. Horowitz, dated June 22, 2023.
Exhibit 99.1 Joint Filing Agreement